Acadian Asset Management’s Lexicon Pharmaceuticals LXRX Stock Holding History

Acadian Asset Management’s Portfolio LXRX Stock Details LXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$693K	Sell	445,288 -194,842	-30%	-$283K	﹤0.01%	1268
2025 Q4	$732K	Buy	640,130 +603,225	+1,635%	+$829K	﹤0.01%	1203
2025 Q3	$49K	Buy	+36,905	New	+$41.9K	﹤0.01%	1647
2025 Q2	–	Sell	-573,688	Closed	-$263K	–	1767
2025 Q1	$263K	Buy	+573,688	New	+$362K	﹤0.01%	1203
2024 Q4	–	Sell	-58,007	Closed	-$91K	–	1941
2024 Q3	$91K	Buy	+58,007	New	+$103K	﹤0.01%	1618
2021 Q2	–	Sell	-462,296	Closed	-$2.71M	–	2122
2021 Q1	$2.71M	Sell	462,296 -1,231,739	-73%	-$8.53M	0.01%	649
2020 Q4	$5.79M	Sell	1,694,035 -160,275	-9%	-$306K	0.02%	466
2020 Q3	$2.67M	Buy	1,854,310 +191,384	+12%	+$341K	0.01%	592
2020 Q2	$3.31M	Buy	1,662,926 +586,865	+55%	+$1.15M	0.01%	581
2020 Q1	$2.1M	Buy	1,076,061 +911,113	+552%	+$2.71M	0.01%	589
2019 Q4	$685K	Buy	+164,948	New	+$635K	﹤0.01%	989
2016 Q4	–	Sell	-4,886	Closed	-$88K	–	1710
2016 Q3	$88K	Sell	4,886 -55,250	-92%	-$889K	﹤0.01%	1084
2016 Q2	$863K	Buy	+60,136	New	+$816K	﹤0.01%	657

Other funds holding LXRX

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Acadian Asset Management's LXRX Position: Q1 2026 in Review

Acadian Asset Management reduced its Lexicon Pharmaceuticals (LXRX) stake by 30% in Q1 2026, selling an estimated $283K and leaving 445,288 shares worth $693K. The position accounts for ﹤0.01% of the portfolio, ranked #1268.

Acadian Asset Management first reported a position in LXRX in Q2 2016 and has held it in 13 quarters since. The position peaked at $5.79M in Q4 2020. 136 funds tracked by Wall St. Rank hold LXRX as of Q1 2026.

Acadian Asset Management held 445,288 shares of Lexicon Pharmaceuticals worth $693K as of Q1 2026.
Acadian Asset Management sold 194,842 Lexicon Pharmaceuticals shares in Q1 2026, an estimated $283K.
Lexicon Pharmaceuticals made up ﹤0.01% of Acadian Asset Management's portfolio in Q1 2026, its #1268 holding.
Acadian Asset Management first reported a position in Lexicon Pharmaceuticals in Q2 2016 and has held it in 13 quarters since.
Acadian Asset Management's Lexicon Pharmaceuticals position peaked at $5.79M in Q4 2020.
136 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q1 2026.

Based on Acadian Asset Management's 13F filing for Q1 2026, filed 13 May 2026.